Login here to update your profile  
My Profile

Kevin Nash,  Ph.D.
Assistant Professor, Dept. of Molecular Pharmacology and Physiology, College of Medicine


Primary Department: COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY

Assistant Professor
COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY

profile Image
Contacts
Email: knash@health.usf.edu
Phone: (813) 974-3788
Office: ALZ, 421
Mailing address 12901 Bruce B. Downs Blvd. MDC 8
Tampa, FL 33612
 
Education
  • Ph.D. , Biochemistry, University of Queensland , Queensland, Australia - 1996.
  • PHD, Biochemistry, University Of Queensland , Australia - 1996.
  • B.S., Biochemistry and Microbiology, University of Queensland , Queensland, Australia - 1991.
  •  
    Interdisciplinary & Emerging Signature Programs
    Neurodegenerative Disease, Neuroscience.
     
    Research Summary

    My research focus is now targeted towards using recombinant Adeno-associated virus (rAAV) to study of neurological disorders. We have examined the use of rAAV to over express proteases including neprilysin (NEP), insulin degrading enzyme (IDE; also known as insulysin) and endothelin converting enzyme (ECE) to remove beta-amyloid which is deposited in Alzhiemer disease. To facilitate the diffusion of the protease enzymes to the amyloid plaques, we have engineered the proteins with a signal peptide triggering secretion. We have successfully observed a reduction in amyloid plaques with both NEP and ECE in APP+PS1 transgenic Alzheimer mice models. We are also using rAAV to study an inflammatory molecule known as Fractalkine. Fractalkine reduces the pro-inflammatory response that is observed in many neurological diseases. We are examining whether this reduction in inflammation would be beneficial in Alzheimer and Parkinson’s diseases.

     


    Selected Publications
  • Selenica, ML.Benner, L.Housley, SB.Manchec, B.Lee, DC.Nash, KR.Kalin, J.Bergman, JA.Kozikowski, A.Gordon, MN.Morgan, D. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's research & therapy. 6(1): 12, 2014.
  • Nash, KR.Moran, P.Finneran, DJ.Hudson, C.Robinson, J.Morgan, D.Bickford, PC. Fractalkine Over Expression Suppresses α-Synuclein-mediated Neurodegeneration. Molecular therapy : the journal of the American Society of Gene Therapy. (): , 2014.
  • Nash, KR.Lee, DC.Hunt, JB.Morganti, JM.Selenica, ML.Moran, P.Reid, P.Brownlow, M.Guang-Yu Yang, C.Savalia, M.Gemma, C.Bickford, PC.Gordon, MN.Morgan, D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiology of aging. 34(6): 1540-8, 2013.
  • Lee, DC.Ruiz, CR.Lebson, L.Selenica, ML.Rizer, J.Hunt, JB.Rojiani, R.Reid, P.Kammath, S.Nash, K.Dickey, CA.Gordon, M.Morgan, D. Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiology of aging. 34(6): 1610-20, 2013.
  • Carty, N.Nash, KR.Brownlow, M.Cruite, D.Wilcock, D.Selenica, ML.Lee, DC.Gordon, MN.Morgan, D. Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PloS one. 8(3): e59626, 2013.
  • Selenica, ML.Alvarez, JA.Nash, KR.Lee, DC.Cao, C.Lin, X.Reid, P.Mouton, PR.Morgan, D.Gordon, MN. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. Journal of neuroinflammation. 10(): 86, 2013.
  • Li, Q.Lebson, L.Lee, DC.Nash, K.Grimm, J.Rosenthal, A.Selenica, ML.Morgan, D.Gordon, MN. Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 7(1): 202-14, 2012.
  • Nash, KR.Cardenas-Aguayo, MC.Berg, MJ.Marks, N. Transduction of E13 murine neural precursor cells by non-immunogenic recombinant adeno-associated viruses induces major changes in neuronal phenotype. Neuroscience. 210(): 82-98, 2012.
  • Daily, JL.Nash, K.Jinwal, U.Golde, T.Rogers, J.Peters, MM.Burdine, RD.Dickey, C.Banko, JL.Weeber, EJ. Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome. PloS one. 6(12): e27221, 2011.
  • Choi, YK.Nash, K.Byrne, BJ.Muzyczka, N.Song, S. The effect of DNA-dependent protein kinase on adeno-associated virus replication. PloS one. 5(12): e15073, 2010.
  • Galleguillos, D.Fuentealba, JA.Gómez, LM.Saver, M.Gómez, A.Nash, K.Burger, C.Gysling, K.Andrés, ME. Nurr1 regulates RET expression in dopamine neurons of adult rat midbrain. Journal of neurochemistry. 114(4): 1158-67, 2010.
  • Carty, N.Lee, D.Dickey, C.Ceballos-Diaz, C.Jansen-West, K.Golde, TE.Gordon, MN.Morgan, D.Nash, K. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of neuroscience methods. 194(1): 144-53, 2010.
  • Lebson, L.Nash, K.Kamath, S.Herber, D.Carty, N.Lee, DC.Li, Q.Szekeres, K.Jinwal, U.Koren, J.Dickey, CA.Gottschall, PE.Morgan, D.Gordon, MN. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(29): 9651-8, 2010.
  • Gorbatyuk, OS.Li, S.Nash, K.Gorbatyuk, M.Lewin, AS.Sullivan, LF.Mandel, RJ.Chen, W.Meyers, C.Manfredsson, FP.Muzyczka, N. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Molecular therapy : the journal of the American Society of Gene Therapy. 18(8): 1450-7, 2010.
  • Nash, K.Chen, W.Salganik, M.Muzyczka, N. Identification of cellular proteins that interact with the adeno-associated virus rep protein. Journal of virology. 83(1): 454-69, 2009.
  • Levy, HC.Bowman, VD.Govindasamy, L.McKenna, R.Nash, K.Warrington, K.Chen, W.Muzyczka, N.Yan, X.Baker, TS.Agbandje-McKenna, M. Heparin binding induces conformational changes in Adeno-associated virus serotype 2. Journal of structural biology. 165(3): 146-56, 2009.
  • Carty, NC.Nash, K.Lee, D.Mercer, M.Gottschall, PE.Meyers, C.Muzyczka, N.Gordon, MN.Morgan, D. Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Molecular therapy : the journal of the American Society of Gene Therapy. 16(9): 1580-6, 2008.
  • Nash, K.Chen, W.Muzyczka, N. Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins. Journal of virology. 82(3): 1458-64, 2008.
  • Nash, K.Chen, W.McDonald, WF.Zhou, X.Muzyczka, N. Purification of host cell enzymes involved in adeno-associated virus DNA replication. Journal of virology. 81(11): 5777-87, 2007.
  • Mandel, RJ.Manfredsson, FP.Foust, KD.Rising, A.Reimsnider, S.Nash, K.Burger, C. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Molecular therapy : the journal of the American Society of Gene Therapy. 13(3): 463-83, 2006.
  • Kohlbrenner, E.Aslanidi, G.Nash, K.Shklyaev, S.Campbell-Thompson, M.Byrne, BJ.Snyder, RO.Muzyczka, N.Warrington, KH.Zolotukhin, S. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Molecular therapy : the journal of the American Society of Gene Therapy. 12(6): 1217-25, 2005.
  • Burger, C.Nash, K.Mandel, RJ. Recombinant adeno-associated viral vectors in the nervous system. Human gene therapy. 16(7): 781-91, 2005.
  • Rodriguez-Lebron, E.Denovan-Wright, EM.Nash, K.Lewin, AS.Mandel, RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Molecular therapy : the journal of the American Society of Gene Therapy. 12(4): 618-33, 2005.
  • Valizadeh, M.Schenk, G.Nash, K.Oddie, GW.Guddat, LW.Hume, DA.de Jersey, J.Burke, TR.Hamilton, S. Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases. Archives of biochemistry and biophysics. 424(2): 154-62, 2004.
  • Dunn, BM.Pennington, MW.Frase, DC.Nash, K. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Biopolymers. 51(1): 69-77, 1999.
  • Marshall, K.Nash, K.Haussman, G.Cassady, I.Hume, D.de Jersey, J.Hamilton, S. Recombinant human and mouse purple acid phosphatases: expression and characterization. Archives of biochemistry and biophysics. 345(2): 230-6, 1997.
  • Nash, K.Feldmuller, M.de Jersey, J.Alewood, P.Hamilton, S. Continuous and discontinuous assays for phosphotyrosyl protein phosphatase activity using phosphotyrosyl peptide substrates. Analytical biochemistry. 213(2): 303-9, 1993.

  • Positions Held
  • Research Assistant Professor (Powell Centre for Gene Therapy, University of Florida 2002 - 2007)


  • Memberships
  • The American Association for the Advancement of Science (Member, 2008 - Present)
  • American Society of Gene Therapy (Member, 2008 - Present)
  • Society for Neuroscience (Member, 2008 - Present)


  • Patents & Licensing
  • Pseudotyping of recombinant AAV verions (Snyder et al.) Patent pending (US Application No. 60/385,864 - 2008)


  • Profile last modified on 08/23/2013